By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Athena Diagnostics, a subsidiary of Thermo Fisher Scientific, has licensed from Toronto's Centre for Addiction and Mental Health the rights to develop a test for intellectual disability based on CC2D2A gene mutations.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.